People: Verenium Corp (VRNM.W)

Summary

Name	Age	Since	Current Position
James Cavanaugh	75	1998	Independent Chairman of the Board
James Levine	41	2011	President, Chief Executive Officer, Director
Jeffrey Black	43	2011	Chief Financial Officer, Senior Vice President
Janet Roemer	56	2010	Chief Operating Officer, Executive Vice President - Specialty Enzymes Business Unit
Alex Fitzpatrick	45	2010	Senior Vice President, General Counsel, Secretary
Holger Liepmann	61	2013	Director
John Dee		2008	Independent Director
Peter Johnson	66	1999	Independent Director
Fernand Kaufmann	69	2004	Independent Director
Joshua Ruch		2007	Independent Director
Cheryl Wenzinger	63	2004	Independent Director

» Insider Trading

Biographies

Name	Description
James Cavanaugh	Dr. James Henry Cavanaugh, Ph.D., is Independent Chairman of the Board of Verenium Corporation. He has been a director of Verenium since 1992 and Verenium’s Chairman since 1998. Dr. Cavanaugh has been a Managing Director of HealthCare Ventures LLC, a venture capital management company since 1988. Dr. Cavanaugh was formerly president of SmithKline & French Laboratories U.S., Inc., the pharmaceutical division of SmithKline Beckman Corporation. Previously, he was President of Allergan International, a specialty eye care company. Prior to his industry experience, Dr. Cavanaugh was Deputy Assistant to the President for Domestic Affairs and Deputy Chief of the White House staff. Dr. Cavanaugh holds a Doctorate and a Master’s degree from the University of Iowa and a Bachelor of Science degree from Fairleigh Dickinson University. In addition to serving on the Board of Directors of several privately held health care and biotechnology companies, he was non-executive chairman of Shire Pharmaceuticals Group plc from 1999 to 2008. He served on the Board of MedImmune, Inc. from 1990 until it was acquired by AstraZeneca in 2007, and was Chairman of Vicuron Pharmaceuticals, Inc. from its inception until it was acquired by Pfizer in 2005. Dr. Cavanaugh currently serves on the Board of SkinMedica, Inc.
James Levine	Mr. James E. Levine is President, Chief Executive Officer, Director of Verenium Corporation since March 2011. He joined Verenium in April 2009 as Executive Vice President and Chief Financial Officer. Prior to joining Verenium, Mr. Levine held various positions focused on the energy and healthcare industries with the global investment banking and securities firm, Goldman Sachs & Co., where he most recently served as a Managing Director in the Power and Utilities Group in New York. Before that he served as a Managing Director in the Goldman Sachs Energy Group in London and held positions in the Goldman Sachs Healthcare Group in London and New York focused on biotechnology companies. Prior to Goldman Sachs, Mr. Levine held positions with Lehman Brothers, Inc. in New York, and Industrial Economics, Inc. in Cambridge, Massachusetts. Mr. Levine received an M.B.A. degree with a concentration in Finance from the Wharton School of the University of Pennsylvania and a B.A. in Economics from Brandeis University in Waltham, Massachusetts.
Jeffrey Black	Mr. Jeffrey G. Black is Chief Financial Officer, Senior Vice President of Verenium Corporation since March 2011. Mr. Black joined Verenium in 2005 as Chief Accounting Officer. Mr. Black has 20 years in financial management and advisory roles and has served in senior level financial management roles for six publicly-traded companies. Mr. Black’s experience includes serving as Executive Director of Accounting and Corporate Controller of Isis Pharmaceuticals, Inc. and Principal and Interim Financial Executive of Regent Pacific Management Corporation, a financial advisory firm through which he served as Vice President of Finance and Corporate Controller of Clarent Corporation and Vice President and Corporate Controller of Accelerated Networks, Inc. Mr. Black is a certified public accountant (inactive) and began his career with Ernst & Young LLP. Mr. Black graduated with a bachelor’s degree in business from the University of Arizona.
Janet Roemer	Ms. Janet S. Roemer is Chief Operating Officer, Executive Vice President - Specialty Enzymes Business Unit of Verenium Corporation. She joined Verenium in March 2008, as Executive Vice President of the Specialty Enzymes Business Unit and became Chief Operating Officer of Verenium in July 2010. Prior to joining Verenium, Ms. Roemer held several positions with BP Group, one of the world’s oil and gas companies. She was Chief of Staff to the CEO of Innovene, a $24 billion petrochemical and refining business within BP Group. Prior to that, Ms. Roemer held executive level roles including chief executive of a $1.7 billion North American chemical business, Vice President of Digital Business, and General Manager of a $700 million global chemical business. Ms. Roemer also held various positions at Amoco Corporation between 1983 and 1999, in sales and marketing management, product management, production planning and logistics, and strategic planning. She began her career as a chemist at National Starch and Chemical. Ms. Roemer received an M.B.A. from the University of Chicago, and a Bachelor’s degree in Chemistry from Miami University in Oxford, Ohio.
Alex Fitzpatrick	Mr. Alexander A. Fitzpatrick is the Senior Vice President, General Counsel, Secretary of Verenium Corporation., since November 2010. Prior to joining Verenium, Mr. Fitzpatrick served as Senior Vice President, General Counsel and Secretary of Kintera, Inc, a publicly traded technology company. Following the sale of Kintera, Mr. Fitzpatrick continued to serve in a similar position for a division of Blackbaud, Inc. Previously, Mr. Fitzpatrick was Director of Strategic Transactions for a division of Vivendi Universal SA. Prior to that, as a member of the business, corporate and technology departments with the law firms Cooley LLP and Latham & Watkins LLP in San Diego, and Rogers & Wells LLP (now Clifford Chance) in London, Mr. Fitzpatrick represented biotech and other technology companies, investment banks and venture capitalists in a variety of transactions including numerous collaborations, mergers and acquisitions, intellectual property matters, licensing and financing activity. Mr. Fitzpatrick received a B.S. in mathematics from Georgetown Universityand a J.D. from the University of California, Berkeley.
Holger Liepmann	Mr. Holger A. Liepmann has been appointed as the Director of Verenium Corp. effective March 31, 2013. Mr. Liepmann retired two years ago from Abbott Laboratories, a global health care company, where he spent 25 years in various positions gaining progressively greater responsibilities in the company throughout his career. Most recently, he served as Executive Vice President of Global Nutrition where he was responsible for all facets of the company's business with sales exceeding $5.5 billion. In this role, Mr. Liepmann helped the Global Nutrition group grow market share globally in the U.S. and significantly expanding international sales. Prior to that, he served as Executive Vice President of Abbott's Pharmaceutical Products Group, Senior Vice President of International Operations of the company's ex-U.S. pharmaceutical and nutritional operations, and several other positions with Abbott International, based in various parts of the world. Mr. Liepmann earned a bachelor's degree in Psychology from Dartmouth College and a Masters in Business Administration from Stanford University.
John Dee	Mr. John F. Dee is Independent Director of Verenium Corporation since May 2008. Mr. Dee has been President and Chief Executive Officer of Link Medicine, a privately held biotechnology company advancing novel approaches for the treatment of neurodegenerative diseases, since May 2009. Prior to that, he served as President and Chief Executive Officer of Hypnion, Inc., a privately-held neurosciences drug discovery company, from July 2000 through its acquisition by Eli Lilly and Company in April 2007. Prior to Hypnion, Mr. Dee spent several years in senior executive roles at biotechnology companies, and as a senior consultant at McKinsey & Co., Inc., a management consulting firm, where he led teams of senior executives in the development and implementation of new strategic directives and performance improvements. Previously, Mr. Dee was the Chairman of the Board for NeuroPhage Inc., a neuroscience company focused on neurodegenerative disorders, and before that served as Chairman of the Board for BioProcessors Corporation, a privately-held company focused on advancements in bioprocessing for the life sciences industry. Mr. Dee holds B.A. and M.S. degrees in Engineering from Stanford University and an M.B.A. from Harvard University.
Peter Johnson	Mr. Peter Johnson is Independent Director of Verenium Corporation since 1999. Mr. Johnson was a founder of Agouron Pharmaceuticals, Inc. and served as its President and Chief Executive Officer from its inception in 1984 until 2000. Mr. Johnson currently serves as a director of a nonprofit organization. Mr. Johnson received a B.A. and an M.A. from the University of California.
Fernand Kaufmann	Dr. Fernand J. Kaufmann is Independent Director of Verenium Corporatin since 2004. Dr. Kaufmann retired from The Dow Chemical Company, a public chemical manufacturing company, in 2001. During his more than 30-year career at Dow, Dr. Kaufmann served in a number of senior executive capacities, including Group Vice-President for New Businesses and as a member of Dow’s management executive committee. Dr. Kaufmann currently serves as Chief Executive Officer and chairman of the board of HPL S.A., a Swiss technology start-up company in the field of novel lithium-ion battery technology. Dr. Kaufmann received a Ph.D. in polymer chemistry from the University of Strasbourg in France. He also serves as an advisor to Emerald Technology Ventures, a Swiss venture capital fund focused on clean energy and other technology. Verenium’s Board of Directors has concluded that Dr. Kaufmann should serve as a director of Verenium based upon his experience and record of achievement as both an executive and director of public and private companies in the chemical, energy and biotechnology fields, as well as his tenure since 2004 as a member of the Board, and of the audit committee since 2005, of the Company.
Joshua Ruch	Mr. Joshua Ruch is Independent Director of Verenium Corporation since 2007. Prior to Verenium’s merger with Celunol, was a director of Celunol since December 2004. Mr. Ruch is the Chairman and Chief Executive Officer of Rho Capital Partners, Inc., an investment and venture capital management company, which he co-founded in 1981. Prior to founding Rho, Mr. Ruch was employed in investment banking at Salomon Brothers. Mr. Ruch received a B.S. degree in electrical engineering from the Israel Institute of Technology (Technion) and an M.B.A. from the Harvard Business School. Mr. Ruch is also a director of a number of private companies.
Cheryl Wenzinger	Ms. Cheryl A. Wenzinger is Independent Director of Verenium Corporation since 2004. She serves as the chair of Verenium’s audit committee. In her most recent position as audit partner at Deloitte & Touche from 1984 to 2000, Ms. Wenzinger served many private and public companies, with a focus on health care providers and insurers, manufacturing, and agribusiness. She currently serves on the Board of Directors of Banner Health, where she currently chairs the strategy committee and has chaired the audit committee, and on the Board of Trustees for Delta Dental Plan of Colorado. Ms. Wenzinger received a B.S. in Accounting from the University of Northern Colorado and is a Certified Public Accountant. Ms. Wenzinger served as a member of audit committee, and as chair of the audit committee since 2005.

Basic Compensation

Name	Fiscal Year Total
James Cavanaugh	--
James Levine	1,336,390
Jeffrey Black	499,410
Janet Roemer	598,521
Alex Fitzpatrick	401,255
Holger Liepmann	--
John Dee	--
Peter Johnson	--
Fernand Kaufmann	--
Joshua Ruch	--
Cheryl Wenzinger	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
James Cavanaugh	0	0
James Levine	0	0
Jeffrey Black	0	0
Janet Roemer	0	0
Alex Fitzpatrick	0	0
Holger Liepmann	0	0
John Dee	0	0
Peter Johnson	0	0
Fernand Kaufmann	0	0
Joshua Ruch	0	0
Cheryl Wenzinger	0	0

Insider Trading

Name	Shares Traded	Price
AUSTIN W MARXE ET AL	5,600	$4.40
AUSTIN W MARXE ET AL	16,302	$4.25
AUSTIN W MARXE ET AL	20,000	$4.30
AUSTIN W MARXE ET AL	56,317	$4.30
AUSTIN W MARXE ET AL	47,380	$4.35
LEVINE JAMES E	4,994	$3.65
AUSTIN W MARXE ET AL	289,528	$3.76
AUSTIN W MARXE ET AL	100,000	$3.97
CAVANAUGH JAMES H	37,305	$3.08
CAVANAUGH JAMES H	50,000	$3.10
LEVINE JAMES E	25,000	$3.18
FITZPATRICK ALEXANDER A	7,203	$1.90
ROEMER JANET SKOGAN	5,000	$1.95
FITZPATRICK ALEXANDER A	293	$1.85
BLACK JEFFREY G	1,100	$2.05
BLACK JEFFREY G	125	$1.97
CAVANAUGH JAMES H	54,000	$1.95
BLACK JEFFREY G	450	$1.93
BLACK JEFFREY G	200	$1.91
LEVINE JAMES E	25,000	$1.69
CAVANAUGH JAMES H	21,200	$1.74

» Full list on Insider Trading

People: Verenium Corp (VRNM.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: